These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 27735120)

  • 1. Comparative studies of insulin vs glucagon-like peptide-1 receptor agonists in patients initiating injectable therapy.
    Dejgaard TF; Madsbad S
    Diabetes Obes Metab; 2017 Feb; 19(2):153-155. PubMed ID: 27735120
    [No Abstract]   [Full Text] [Related]  

  • 2. Prioritising injectable therapies in the management of type 2 diabetes.
    Frias JP
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):505-508. PubMed ID: 30981766
    [No Abstract]   [Full Text] [Related]  

  • 3. Semaglutide (Ozempic)--another injectable GLP-1 receptor agonist for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Jan; 60(1539):19-21. PubMed ID: 29364197
    [No Abstract]   [Full Text] [Related]  

  • 4. Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice.
    Artigas CF; Stokes V; Tan GD; Theodorakis MJ
    Expert Opin Pharmacother; 2015; 16(10):1417-21. PubMed ID: 26077113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes injectable therapy: type 2 diabetes management in Danish practice.
    Sterzi D; Auziere S; Jensen MM; Lopes S
    Curr Med Res Opin; 2017 Dec; 33(12):2211-2216. PubMed ID: 28875722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [When injectable diabetes therapy becomes necessary. Insulin or GLP-1 analogs?].
    Stiefelhagen P
    MMW Fortschr Med; 2011 Jan; 153(1-2):14. PubMed ID: 24761480
    [No Abstract]   [Full Text] [Related]  

  • 7. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
    Gupta A; Jelinek HF; Al-Aubaidy H
    Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-weekly glucagon-like peptide 1 receptor agonists.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2015 Jul; 65(7):796-8. PubMed ID: 26160096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?
    Goncalves E; Bell DSH
    Diabetes Obes Metab; 2017 Jun; 19(6):909-911. PubMed ID: 28176440
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
    Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
    Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Injectable Drug for Type 2 Diabetes.
    Aschenbrenner DS
    Am J Nurs; 2016 Nov; 116(11):22-23. PubMed ID: 27787319
    [No Abstract]   [Full Text] [Related]  

  • 12. Injectable combination therapies for the management of diabetes: an Indian perspective.
    Dutta D; Khandelwal D; Kalra S
    Expert Opin Drug Metab Toxicol; 2020 Mar; 16(3):209-216. PubMed ID: 32098522
    [No Abstract]   [Full Text] [Related]  

  • 13. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
    Darmon P; Raccah D
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
    Baron HL
    J Fam Pract; 2017 Oct; 66(10 Suppl):S17-S28. PubMed ID: 28991933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association.
    Cariou B
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S28-6S35. PubMed ID: 26774017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are basal and glucagon-stimulated C-peptide values predictors of response to GLP-1 receptor agonists in type 2 diabetic patients?
    Maiza JC; Gérard P; Rollot O; Cogne M; Jarlet E; Schneebeli S
    Minerva Endocrinol; 2016 Mar; 41(1):138-40. PubMed ID: 26878563
    [No Abstract]   [Full Text] [Related]  

  • 17. Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.
    Nreu B; Dicembrini I; Tinti F; Mannucci E; Monami M
    Diabetes Res Clin Pract; 2020 Mar; 161():108087. PubMed ID: 32084455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Modern antihyperglycaemic agents--what is the patient benefit?].
    Siegmund T
    MMW Fortschr Med; 2016 Apr; 158(7):45-8. PubMed ID: 27071585
    [No Abstract]   [Full Text] [Related]  

  • 19. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
    Edelman SV
    J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Not Available].
    Fischli S; Henzen C
    Ther Umsch; 2017; 74(8):433-439. PubMed ID: 29461151
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.